Actinogen Medical Ltd - Asset Resilience Ratio
Actinogen Medical Ltd (ACW) has an Asset Resilience Ratio of 74.78% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Actinogen Medical Ltd (ACW) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Actinogen Medical Ltd's Asset Resilience Ratio has changed over time. See Actinogen Medical Ltd (ACW) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Actinogen Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Actinogen Medical Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$19.02 Million | 74.78% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$19.02 Million | 74.78% |
Asset Resilience Insights
- Very High Liquidity: Actinogen Medical Ltd maintains exceptional liquid asset reserves at 74.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Actinogen Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Actinogen Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Actinogen Medical Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Actinogen Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 33.86% | AU$7.22 Million ≈ $5.11 Million |
AU$21.31 Million ≈ $15.08 Million |
-13.35pp |
| 2023-06-30 | 47.21% | AU$7.18 Million ≈ $5.08 Million |
AU$15.21 Million ≈ $10.76 Million |
-4.71pp |
| 2022-06-30 | 51.92% | AU$12.10 Million ≈ $8.56 Million |
AU$23.31 Million ≈ $16.49 Million |
+13.28pp |
| 2021-06-30 | 38.63% | AU$7.10 Million ≈ $5.02 Million |
AU$18.38 Million ≈ $13.00 Million |
+8.77pp |
| 2020-06-30 | 29.87% | AU$3.56 Million ≈ $2.52 Million |
AU$11.94 Million ≈ $8.45 Million |
-17.21pp |
| 2019-06-30 | 47.08% | AU$7.64 Million ≈ $5.40 Million |
AU$16.22 Million ≈ $11.48 Million |
-7.83pp |
| 2018-06-30 | 54.90% | AU$9.90 Million ≈ $7.00 Million |
AU$18.03 Million ≈ $12.75 Million |
+15.83pp |
| 2017-06-30 | 39.07% | AU$3.99 Million ≈ $2.82 Million |
AU$10.21 Million ≈ $7.22 Million |
+7.98pp |
| 2016-06-30 | 31.09% | AU$4.03 Million ≈ $2.85 Million |
AU$12.95 Million ≈ $9.16 Million |
-- |
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more